P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy by Yu, H., Goldberg, S., Le, X., Piotrowska, Z., Smith, P., Mensi, I., Kirova, B., Chmielecki, J., Li-Sucholeicki, X., Szekeres, P., Doughton, G., Patel, G., Jewsbury, P., Riess, J.

Get full text